How were OncoSec Medical's earnings last quarter?

OncoSec Medical Incorporated (NASDAQ:ONCS) posted its quarterly earnings data on Tuesday, December, 14th. The biotechnology company reported ($5.50) EPS for the quarter, beating analysts' consensus estimates of ($8.14) by $2.64.

When did OncoSec Medical's stock split?

OncoSec Medical's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Punit Dhillon's approval rating as OncoSec Medical's CEO?

2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com . Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of OncoSec Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK) , Inovio Pharmaceuticals (INO) , XOMA (XOMA) , Anavex Life Sciences (AVXL) , Walt Disney (DIS) , Idera Pharmaceuticals (IDRA) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Dynavax Technologies (DVAX) and Trevena (TRVN) .

NASDAQ:ONCS

OncoSec Medical (ONCS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ONCS Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.20
▼
$0.94
52-Week Range: N/A

Volume: 52.49 million shs
Average Volume: 2.22 million shs
Market Capitalization: $1.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get OncoSec Medical alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About OncoSec Medical Stock (NASDAQ:ONCS)

OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer. Its pipeline also comprises TAVO +nivolumab, which is in Phase 2 clinical trial for the treatment of breast cancer; TAVO + CXCL9 for the treatment of solid tumors; and OMS-100 and OMS-102, which are in Phase 2 clinical trial for the treatment of metastatic melanoma. OncoSec Medical Incorporated has clinical trial collaborations with Merck & Co., Inc. and its subsidiary in connection with the KEYNOTE-695 and KEYNOTE-890; and a research collaboration with Duke University's Center for Applied Therapeutics to evaluate TAVO in combination or sequenced with a HER2-plasmid vaccine. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in Pennington, New Jersey.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

ONCS Stock News Headlines

June 24, 2023 | finance.yahoo.com

ONCS - OncoSec Medical Incorporated

June 23, 2023 | markets.businessinsider.com

Why Is OncoSec Medical (ONCS) Stock Up 100% Today?

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

June 15, 2023 | msn.com

Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

June 15, 2023 | msn.com

Why Is OncoSec Medical (ONCS) Stock Down 48% Today?

May 18, 2023 | finance.yahoo.com

OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 16, 2023 | msn.com

OncoSec Medical plunges 35% lower on sale of 1.4M shares of common stock

May 16, 2023 | finance.yahoo.com

OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

May 16, 2023 | finance.yahoo.com

OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program

April 27, 2023 | finance.yahoo.com

OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program

April 11, 2023 | finance.yahoo.com

OncoSec Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

April 10, 2023 | msn.com

Why OncoSec Medical Shares Are Soaring Today

April 10, 2023 | finance.yahoo.com

OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

April 6, 2023 | benzinga.com

OncoSec Medical Inc (ONCS) is lower by 6.15% Tuesday In Premarket Trading

April 3, 2023 | finance.yahoo.com

OncoSec Shares Disappointing Results From Skin Cancer Combo Therapy Trial, Sets Stage For Neoadjuvant Setting Study

April 3, 2023 | msn.com

OncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trial

April 3, 2023 | finance.yahoo.com

OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

March 1, 2023 | marketwatch.com

OncoSec Medical Withdraws Planned Offering, Shares Rise Over 50%

March 1, 2023 | msn.com

Why is OncoSec Medical (ONCS) Stock Up 91% Today?

January 16, 2023 | reuters.com

ONCS.OQ - | Stock Price & Latest News | Reuters

January 5, 2023 | benzinga.com

OncoSec Medical Stock (NASDAQ:ONCS), Quotes and News Summary

December 8, 2022 | msn.com

Peering Into OncoSec Medical's Recent Short Interest

December 5, 2022 | finance.yahoo.com

OncoSec to Present at the RHK Capital Disruptive Growth Conference on December 6, 2022

November 30, 2022 | marketwatch.com

OncoSec Shares Drop 25% on Equity Offer Pricing After 51% Tuesday Surge

November 30, 2022 | finance.yahoo.com

OncoSec Announces Pricing of $3.5 Million Public Offering

November 24, 2022 | finance.yahoo.com

OncoSec Touts Encouraging Early Data For Opdivo Combined Immunotherapy For Skin Cancer

See More Headlines

Receive ONCS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoSec Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 12/14/2021
Today: 4/19/2024
Fiscal Year End: 7/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:ONCS
CUSIP: N/A
CIK: 1444307
Web: www.oncosec.com
Phone: (855) 662-6732
Fax: 858-430-3832
Employees: 40
Year Founded: 2011

Profitability

EPS (Most Recent Fiscal Year): ($15.2865)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-34,180,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -868.29%
Return on Assets: -160.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.89
Quick Ratio: 0.89

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.42 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,550,000
Free Float: 4,494,000
Market Cap: $1.26 million
Optionable: Not Optionable
Beta: 1.99

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Robert H. Arch
President, CEO & Non-Independent Director
George Chi
Chief Financial Officer
David Canton
Vice President-Research & Development
Sandra Aung
Chief Clinical Development Officer & Senior VP
Bridget O'Keeffe
Vice President-Clinical Development

Key Competitors

View All Competitors

ONCS Stock Analysis - Frequently Asked Questions

How were OncoSec Medical's earnings last quarter?: OncoSec Medical Incorporated (NASDAQ:ONCS) posted its quarterly earnings data on Tuesday, December, 14th. The biotechnology company reported ($5.50) EPS for the quarter, beating analysts' consensus estimates of ($8.14) by $2.64.
When did OncoSec Medical's stock split?: OncoSec Medical's stock reverse split on the morning of Wednesday, November 9th 2022. The 1-22 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What is Punit Dhillon's approval rating as OncoSec Medical's CEO?: 2 employees have rated OncoSec Medical Chief Executive Officer Punit Dhillon on Glassdoor.com. Punit Dhillon has an approval rating of 50% among the company's employees. This puts Punit Dhillon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of OncoSec Medical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), Inovio Pharmaceuticals (INO), XOMA (XOMA), Anavex Life Sciences (AVXL), Walt Disney (DIS), Idera Pharmaceuticals (IDRA), Sorrento Therapeutics (SRNE), Amarin (AMRN), Dynavax Technologies (DVAX) and Trevena (TRVN).

This page (NASDAQ:ONCS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

OncoSec Medical (ONCS) Stock Price, News & Analysis

About OncoSec Medical Stock (NASDAQ:ONCS)

ONCS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

ONCS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info